Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's

30th April 2026 Uncategorised 0

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at least one set of analysts—isn’t sweating what appears to be a slower-than-expected liftoff compared with Novo Nordisk’s rival Wegovy pill.

More: Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
Source: fierce